Polyphor appoints Gökhan Batur as Chief Commercial Officer Dienstag, 09. April 2019 - 07:00

Polyphor AG / Key word(s): Personnel
Polyphor appoints Gökhan Batur as Chief Commercial Officer

09-Apr-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Allschwil, Switzerland, April 9, 2019

Polyphor appoints Gökhan Batur as Chief Commercial Officer

Polyphor AG (SIX: POLN), a clinical stage, Swiss biopharmaceutical company
focused on the discovery and development of antibiotics and immuno-oncology
compounds today announced the appointment of Gökhan Batur to the newly
created position of Chief Commercial Officer (CCO). With over 14 years of
healthcare industry experience, he joins the organization from MSD (known as
Merck & Co. Inc. in the US and Canada), most recently serving as Executive
Director, Global Brand Leader, Antibiotics, working in Switzerland and the
US.

Mr. Batur, who joins effective June 3rd, will be responsible for leading all
commercial activities, including market preparation for our lead antibiotic
murepavadin and our immuno-oncology compound balixafortide. As a member of
the executive management he will lead Polyphor's Commercial activities, as
well as the Business Development & Licensing team.

"I'm very pleased to welcome Gökhan to Polyphor as we look forward to key
milestones in our antibiotic and immuno-oncology programs and continue
building our team for the future," says Giacomo Di Nepi, Chief Executive
Officer of Polyphor. "Gökhan's deep cross departmental and commercial
leadership experience including launching multiple antibiotics in the entire
world will be essential as we start the market preparation for our products,
and we build the late-stage development and commercial capabilities needed
to become a sustainable, multi-product biopharmaceutical company."

Mr. Batur has held positions of increasing responsibility at MSD, most
recently serving as Executive Director, Global Brand Leader, Antibiotics
responsible for leading the global commercial strategy and execution for the
entire Merck antibiotics portfolio managing multiple in-line, launch and
pipeline products and sales of ~2 billion dollars. Prior to this role he was
Executive Director, Global Brand Leader, Gram Negative Antibiotics. Previous
roles at MSD included Executive Director, Hospital Acute Care Franchise for
Emerging Markets and China and, before, he held positions both at regional
and country level in marketing and sales including regional marketing leader
for Hospital Products and Oncology in the EEMEA region. He received his BS
in Management Information Systems from Bosphorus University, Istanbul.


For further information please contact:

For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com

For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the
discovery and development of antibiotics and immuno-oncology compounds. It
has discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical
priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline
of further preclinical antibiotics based on its OMPTA platform. In addition,
Polyphor is developing an immuno-oncology candidate, balixafortide
(POL6326), which is starting a Phase III trial in combination with eribulin
in patients with advanced breast cancer, and exploring in parallel its
potential for further combinations and indications. Polyphor is based in
Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
For more information, please visit www.polyphor.com.


Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of the Polyphor management. Known and
unknown risks, uncertainties, and other factors could lead to material
differences between the forward-looking statements made here and the actual
development, in particular Polyphor's results, financial situation, and
performance. Readers are cautioned not to put undue reliance on
forward-looking statements, which speak only of the date of this
communication. Polyphor disclaims any intention or obligation to update and
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------